International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Challenges and Solutions in Blood Sample Preparation

Fadhel Abdulhadi Alhashem[1], Elwiah Abdullah Alhashem[2], Naji Hussain Saleh Alhassan[3], Ahmed Abdulhamid Alahmed[4], Mohammed Hussain Abdullah Alturaiki [5]

[1,5]Laboratory Specialist, KFHH, Alahssa Health Cluster
[2]Laboratory Specialist, MCH, Alahssa Health Cluster
[3]Laboratory Technician, ORL, Alahssa Health Cluster
[4]Laboratory Technician, KFHH, Alahssa Health Cluster

Abstract
Through the training courses performed, successful results could be achieved in increasing the efficiency of the phlebotomy process, ensuring a reduced rate of hemolysis, ensuring that all bio-chemical samples are collected according to the procedures, reducing the rate of mislabeled and tapered samples, and not collecting samples from the hormone disruptor and tourniquet application.

Keywords: Blood Sample, Blood Collection, Sample Preparation, Laboratory, Waste Managment

1. Introduction

In apheresis, cardiological procedures were not performed by the relevant personnel and various complications such as nerve damage, vasovagal syncope, vasovagal syncope occurred during this procedure. The quality of the sample is expected to increase by mandating to conduct the training not to be indifferent or unaware of the personnel who are not phlebotomists, developing methods such as paying special attention to not applying lowercase, thus taking steps to prevent the error in diagnosing patients and to treat them correctly.

In everyday clinical laboratory practice, the most resourceful and experienced personnel undertake regular responsibilities such as blood sampling, and this duty is estimated to be performed by phlebotomists, nurses, and physicians. Hence, various starting points could be found in determining the causes of misdiagnosis in the blood sample collection and identify the quality of the samples as a barrier in this process. It was established that the risk of diagnosing patients through misdiagnosis substantially increases in the wrong detection of laboratory sample collection independent from the result obtained.

1.1. Importance of Blood Sample Preparation in Medical and Research Settings

The collection of blood samples using the right kind of collection containers plays an important role in effective prevention of hemolysis. Collection of samples in ethylenediaminetetraacetic acid (EDTA), citrate and heparin anticoagulants are very much important in any hospital. The study carried out by further gave the reasons for the avoiding collection of samples in syringes. Same way, it has been noticed that it is not necessary that all the anticoagulants can be sent to the laboratory for biochemical studies. Hemolysis is a major pre-analytical problem in blood analysis and affects clinical interpretation and therapeutic

selection and increases the workload in busy clinical laboratories. Hemolysis is the haemoglobin release of erythrocytes and free hematoporphyrin which gives red color to the serum. A good relationship between puncture site, puncture technique, and regional house staff could take place to diminish the percentage of complications in blood collection.

Biobank sample collections are supposed to reflect the true nature of the human population and occur in large numbers, and biological samples need special attention involving quality-focused strategies. Since the demand for biosamples is increasing, a new approach of "matching quality to purpose" has been started, which aims at sample quality preservation as specifically as needed for the main use [1]. For a relevant group of researchers working on samples from a biobank, pre-analytics have been identified as a major issue. Furthermore, the potential impact of pre-analytical variability on the analytical results might centrally influence post-analytical decisions in personalized medicine era [2]. Together these dominations have led to an anticipated increased focus on strategies for high-quality sample collection and handling. When it comes to blood samples, like their overall importance in diagnostic medical routine, they could be important biosamples reflecting various molecular dimensions with sometimes critical value for medical science.

2. Physical Challenges in Blood Sample Preparation

Hemolysis and clotting are common physical challenges associated with blood sample preparation [3]. Hemolysis can occur during collection, caused either by drawing blood through the needle too forcefully or the venipuncture device being too narrow, which shears the red blood cells. Faulty needles, such as those with small-bore lumens, are a likely culprit in the case of patient injury or discomfort during blood collection. Hemolysis can also result when blood is not collected properly using vacuum tubes, while inappropriate storage or shipping of the evacuated tube system can lead to incorrect results. Finally, if a patient is already taking anticoagulants, failure to invert blood collection tubes immediately and gently (to ensure proper mixing) can lead to sample clotting. Moreover, there is a high risk of sample retrieval, handling, and analysis errors when an analytical instrument uses the vacuum tube as a port [4]. Solutions to these problems could be directed at the engineering sciences. For instance, proper material science engineering in the development of new venipuncture devices, tubes, and vials can minimize hemolysis. Additionally, proper tube engineering can avoid issues such as clotting and sample adhesion. Also, sample-handling errors could be avoided by robotics.

2.1. Hemolysis and its Impact on Test Results

The most used body fluid in diagnosis is blood. Thus, it is important to ensure that collection, handling, and storage processes for blood are appropriate so that results are as reliable as possible [5]. Ideally, the main objectives for handling a sample from technical preanalytical processing (centrifugation) to testing should be to maintain the in vitro integrity and composition of the original sample, and to ensure representative subsampling of the sample during biochemical analysis. For handling of blood samples, it is important to minimize the risk of hemolysis. Hemolysis occurs when hemoglobin leaks out into the plasma, leading to spectral errors in laboratory analysis. Hemolysis can occur either inside the patient's body or can be introduced outside the body using handling procedures. In clinical laboratory, in vitro hemolysis is regarded as a major source of preanalytical variation for plasma/serum analyte results, with a percentage of 60–70% of unsuitable samples due to this cause. Some analytes such as K, lactate dehydrogenase (LD), and free hemoglobin are greatly affected. LD even quadruples if K increases by a factor of 1.0.6 Hemolysis (in vitro) is a frequent cause for rejection of blood samples at labs and even

more influenced by handlings out of analyzers in pretest phases, such as multicylinder needles by BD, lack of rigor in the usage of syringes and the application of wrong test tubes causing mechanical hemolysis by the breaking of blood cells. As in many other assays potassium calibration is traceable to water standards the accurate measurement of K in blood samples is crucial for comparability of results especially because fine differences can be decisive in some clinical settings i.e., hypertension, severe arrhythmia, or end stage renal failure. Beside its essential role in acid-base-homeostasis, erythrocyte metabolism is responsible for the release of considerable amounts of plasma analytes in consequence of the lysis of erythrocytes. Performing analytical tests under detectable concentrations in vitro could levy only a non-importance on hemolysis in contrast to measurements above this level that lead to drastic (pathologic) changes of measured analytes whereby in worst case diagnosis and treatment can be influenced. Concerning the kallikrein-kinin-system surfing on erythrocyte surfaces, the release of its preequilibrium active components KNG, kininogen and kinin could reduce the reliability of the coagulation investigations. Therapy monitoring namely APA-receptor blockade by ACE inhibitors, NEP inhibitors, AT1 receptor blockade is jeopardized if already the basal level is impacted].

3. Chemical Challenges in Blood Sample Preparation

Sample preparation techniques have been widely used for the analysis of biological fluids [7]. Determination of noncovalent interactions in buffering media is an important complexation study. Especially intended for biological applications, reactions occurring in such solutions are mostly accompanied by protein misfolding. In this work, the intermolecular interaction of Na+, K+, and Mg+ ions with myoglobin (Mb) and hemoglobin (Hb) were studied by monitoring the near- and the far-ultraviolet (UV) spectra and 2D-fluorescence spectra of these systems. Mg+, Na+, and K+ cations enhanced the fluorescence intensity, while the position of the emission band was red-shifted due to greater exposure of hydrophobic areas in the protein molecule. These were decisive in the discussion of static quenching or dynamic quenching and the mode of interaction. The expressed structure change of the protein molecule is particularly associated with exposure of some amino acid residues to the aqueous environment, which is why the fluorescence intensity of tyrosine (Tyr) and tryptophan (Trp) changes [8]. Proteins are globular macromolecules, and when a native protein solution meets a hydrophobic surface, this could lead to denaturation of the protein. At interfaces, interaction of analytes with other molecules can change. The parent protein changes after adhesion to the substrate surface in such a way that the immobilized biomacromolecule is no longer in the native structure. This defines the base that researchers have paid special attention to substrate development, the idea being that the interaction of biomacromolecules with the substrate, even if adsorbed in a weakly chemically modified and thereby hydrophilic version form, is a structural cause of the perturbation. 9

3.1. Anticoagulant Interference

Vacuum blood collection vessels are a type of vessel specially used to collect blood samples. They are composed of a plastic injection needle, gas release valve, vacuum blood collectors, and other main components. And the role of the vacuum blood collector is largely determined by the closure (stopper). The following are three types: ① Silica gel: When it is a dry state, barium-like termination, and high-quality silicon; ② Activated charcoal: This type of termination not only prevents blood coagulation but also involves activated charcoal in the instrument to neutralize inflammatory factors and toxic matter, and is suitable for examining toxic gases, the detection of antibodies and chemical substance detection, etc; and ③ Hollow fiber: In addition to the work of a common-stop, it can also play the role of plasma

separator. When using the vacuum blood collection container, the closure is not only a part of the anticoagulant material, but it also plays an important role in sealing the vessel. If the choice is correct, a more secure determination result can be obtained. It is worth noting that some references indicate that the overall rate of insufficient blood samples is as high as 25% for certain test items, more often because the blood could not be separated from the blood collection container in time. It also points out that the AK, D-D, HCY, FIB, TT, PT, APTT, VDRL sensitivity, accurateness, and standardization are reduced because the sample is not separated from the blood collection container in time. The appropriate separation time for blood is another issue. In conclusion, tubes sprayed with heparin lithium salt have a maximum of 48 hours with no significant bias, since the interferences caused by hemolysis are masked in the presence of heparin in most assays. When delayed handling cannot be avoided, samples for fibrinolysis and D-dimer testing must not be anticoagulated with heparin for more than 24 hours. Due to the complexity of the hemostasis system, each test should be individually evaluated to determine the stability of samples delayed before analyzing samples. Heparin also has some interference on some tests such as triglyceride and other tests. When assaying a general blood sample using anticoagulant, a laboratory worker must quickly mix the containers containing blood lairs and anticoagulants and remember not to shake vigorously or turn them upside down.

The choice of anticoagulant and coagulation activation must be considered in advance to avoid coagulation or to minimize activation. The commonly used anticoagulants are EDTA, heparin, or citrate, and they are all necessary to be reversed for the latter convenience [10]. More specifically, when the anticoagulant EDTA (ethylenediamine tetraacetic acid) prevents coagulation by realizing the anticoagulant activity of metallic ion chelation, the dose is generally 1 to 2 mg/mL. Lithium heparin can chelate metallic ions, and because of this, it also has anticoagulant activity. However, this method does not lead to coagulation, but it activates the related coagulation system. 500 I.U. of heparin per ml of blood is generally used as a preventive agent in small-lumen blood vessels, and it can also be applied to prevention in vitro hemostasis, in which the hemostatic test, especially APTT, is often disturbed. Citrate is a doping of the trivalent ion, so chelation reactions effectively prevent blood coagulation. The commonly used treatment drug is sodium citrate. Researchers often use it to prevent coagulation in some blood coagulation test schemes. The dose generally involves 0 to 0.2 ml.

4. Technological Challenges in Blood Sample Preparation

For clinical diagnostic in vitro analysis, the preparation of clean and application-ready targets is essential regarding blood-derived samples. The main part of the clinical chemistry analysis is carried out in biofluids such as plasma or serum. To reach high selectivity and low detection limits, the bioanalysis must deal with the complexity of biofluids [11]. Thus, contamination of the prepared plasma or serum samples can directly disturb analysis results, which could lead to inappropriate medical decisions. This is especially important in low target concentration and thus low signal-to-noise ratio situations.

Blood is a commonly used biofluid, in which analysis and tests are sometimes targeting plasma rather than the whole blood [12]. For any measurements in blood samples, the exclusion of blood cells is frequently necessary [13]. Plasma is the cell-free part of the blood and is used for serum chemistry tests to assess glucose, electrolytes, kidney and liver function, blood disorders, and other types of analyses, including some that can diagnose diseases. Cells and plasma are separated by centrifugation or filtered. Each fraction of blood may contain particulate matter, interfering materials, etc. which are not always present in the same proportion in plasma and in cells.

4.1. Automation vs. Manual Methods

Wherein, complete blood count, blood sedimentation rate, C-reactive protein, serum ferritin, liver function, blood glucose, five routine blood tests of WBC, PLT, lymphocytes, monocytes, and neutrophils will be obtained to evaluate the patient's conditions [1]. The system will use light microscopy images for image acquisition. And the digital image processing and feature extraction and selection are processed by a custom program MATLAB, Python, or a combination of both [1]. Flowchart showed the visit to garage and workshop for the light microscopy images, Generalized Machine Learning Proximal Separable Network framework, feature extraction, selection, and final WBC counting process. Manual Method of Blood Sample Preparation from Conventional Lab Perspective. For manual methods, blood drawing and following all procedures should be handled by trained lab technicians, especially measuring white and red blood cells [1]. Mixing the tube thoroughly and time are crucial, and the follow-up period between both lab assays and test should be within 2h [1]. Besides, when the samples are processed, different pre-analytical factors, such as hemolysis, lack of proper sample volume, and undue clotting, necessitate the need for another blood draw [1]. A reproducible and reliable laser deflectometry system has been developed to solve a similar limitation in hematology analyzers [1]. This new WBC measuring aid could detect the changes in WBC count of blood in a microhematocrit capillary tube from 2.5 × 16.8 1000/ul to 13.2 × 16.8 1000/ul, which was compatible with normal human condition1.

Lab automation aiming to increase laboratory efficiency, eliminate operational errors, free up highly qualified human resources and increase the reliability of measurements is being extensively utilized [1]. The test volume has steadily grown, even during the COVID-19 pandemic, creating a need for more automation [1]. As we enter the age of precision medicine and lifestyle healthcare, this volume is expected to continue to grow [1]. With the progress of analytical instruments and collaborative and personalized medicine, blood sample preparation will play a more important role and evolve based on the perspective of "difference adaptation" [1]. The current study evaluates the gray zone of yellow blood cell (WBC) and thrombocyte (PLT) had been set at 4–12 × 10 communicator 9/L and 100–150 × 10 communicator 9/L, respectively.

5. Regulatory Challenges in Blood Sample Preparation

To minimize the risk of sample and chain errors as well as the associated violations of quality guidelines, several technical solutions are recommended. The need for method-independent, simple, and rapid procedures that are easily integrated into routine laboratory work has resulted in a wide variety of commercial pre-analytic systems for blood collection. To avoid biohazards due to blood or blood-borne infectious materials, blood-drawing systems with new safety lancets which allow stable skin closing and that have a kind of protective shield are discussed. A further main issue in blood collection is how to avoid pre-analytical variables. It is widely disputed as to whether and how certain routine blood analyses are affected by fasting. In this context, different homeostatic parameters, the mode of delivery, the anti-coagulation, the degree of clot activation (even more difficult to monitor in the new gel tubes), the method of transportation, or pathological interferences during in-vivo blood collection should be considered.

Besides the steel needles, with which injuries can still happen, even with safety mechanisms, plastic medical materials, such as lab equipment and tubes, also form a high potential risk for injuries by cutting and stabbing. The pre-analytic phase of the diagnostic work is well known in the literature as a complex and scarcely standardized process, which can cause up to 70% of the TAT. Phlebotomy technicians, who oversee a wide range of activities, are generally evaluated, and compensated according to the number of

patients, rather than on quality. This configuration may contribute to carelessness and a lack of standardization in blood collection [14]. Both the wrong draw order of the different commercially available blood tubes, which can lead to additive carryover from other blood tubes into the subsequent ones, and unsuitable phlebotomist training can have serious consequences for patient safety. Buffer and reagent residues in the hands of the phlebotomist or insufficient mixing can, for example, lead to clot formation or to altered results through additive carryover. Offering accredited and postgraduate phlebotomist training for clinical pathologists could massively improve this situation. In sum, the whole blood collection process requires critical evaluation and continuous monitoring.

Non-standardized closures or colors of vacutainer caps can give rise to sampling confusion for phlebotomists and wrong draw order. The weight of the blood in an anticoagulant to be drawn in milliliters depends on the individual tube size, which is frequently standardized but not by all companies, which could potentially lead to sample volumes not being sufficient or to blood hemolysis, as the mixing ratio of blood and anticoagulant must always be correct. There are also more and more tubes and additives that must be processed directly after blood collection to avoid potential inconveniences due to analytical interferences, such as for glycolysis inhibitors to avoid falsely lower glucose results [15].

5.1. Compliance with Good Laboratory Practices (GLP)

Regular blood plasma sampling from patients at increasing intervals during therapy is time-consuming and poses the risk of sampling errors. Therefore, advancements in blood microsample extraction and the development of advanced laboratory technologies for cancer monitoring are crucial. These technologies should aim to prevent the risk of blood collection errors and process-related biases while providing minimally invasive predictive biomarker information. The European Union Joint Research Center (JRC) under the Cancer Biomarkers (CanBiom) project is working on harmonizing blood sampling and processing steps in different cancer care platforms. However, true harmonized blood sample biobanking still has many limitations that hinder the acceleration of precision medicine research and development [16]. Blood sample standardization is particularly challenging due to the dilution, proteomic biovariability, and variable target gene expression levels.

Blood sample analysis is crucial in clinical practice to diagnose and monitor disease progression or therapeutic efficacy [17]. The preanalytical steps are associated with the highest error rates in blood test preparation and are directly related to sample handling and transport, human mistakes, and low compliance with established guidelines. Because of the high error rates, a substantial number of adverse events in clinical diagnostics have resulted from the preanalytical phase. Additionally, over half of the cost-efficiency of oncology patient care is spent on blood testing, while approximately 51% of the blood tests conducted are associated with avoidable errors stemming from human and process-related factors [15].

6. Environmental Challenges in Blood Sample Preparation

The pre-analytical phase in a clinical diagnostic laboratory encompasses all actions on blood samples collected before clinical analysis. Issues concerning the pre-analytical phase center on positive specimen identification, which verifies the sample quality and integrity from original collection through transport, reception, storage, and preparation. The priority of lab experts is to select the appropriate collection materials and to ensure that the collected blood is mixed accurately with the collection material when it is transported or delivered to the lab. Errors during the pre-analytical phase are easier to identify and ameliorate, which has made this phase the focus of attention. The challenges in the pre-analytical phase of clinical labs management during peak admission periods have been investigated. Long laboratory

turnaround times can be addressed using automated pre-analytical processing units and point-of-care instruments.

Common challenges in blood sample preparation include hemolysis during collection and transport, which can result from improper techniques, handling, or storage [3]. Power outages at site laboratories in remote areas can lead to repeated freeze-thaw cycles, degrading antibodies. Other issues involve maintaining the cold chain during transport and potential specimen mislabeling [4]. Appropriate methods for storage, transport, and processing to prevent biological degradation will help to minimize antibody activity loss. Biological specimens can initiate and propagate different diseases, therefore guidelines for decontamination of processing area and specimen processing equipment are recommended. A study reported a method for the disinfection of processing area and equipment with 0.5% sodium hypochlorite, the use of 1% NaOH as the disinfectant, and the reduction of the risk of cross-transmission in liver biopsy processing.

6.1. Waste Management and Disposal

Ultimately, economic gains were achieved with respect to the defined sustainable structure and discarding system and in theory a social enterprise is an enterprise that is responsible for society [18]. Besides there are three ways that blood waste normalization structure in Turkey is so important. By introducing a blood waste disposal process that will be applied in inpatient services and the outpatient pathologies laboratory will contribute to the decrease of economic burdens of health institutions and corporation responsible issues, If the system is established end to contemplate the predispositives facing societal enterprise performances, the matching process of Turkish members rooted in societal enterprise predictions, and the urgency of societal enterprise expectations. Socially negative aspects of business life like carbon waste production and social energy waste were moved into the backgrounphase. In this context the produce and consumption phases of the projects that worked with fair economic partners were directed to the general resources.

In the laboratories in which this research was conducted, dried blood samples were placed in the solid waste dissolvent containing highly toxic and harmful organic solvents, majority of cytopathogenic chemicals, acidic compounds, and expired blood samples which were collected from certain patients to transfer to a firm referred as firm of hospital revulsion platform to be disposed as waste [19]. To supply it, contracts were signed, and the three-unit cost was shared between the companies as well as the health institutions. We believed that in such situations, the economic expenses for particularly disposable materials of the company would be reduced by eliminating these kinds of waste materials in the hospital's own evidence [20].

7. Ethical Challenges in Blood Sample Preparation

In summary, potential Indigenous participants both want to be asked for their consent and to share the potential benefits associated with their genetic information, but they are concerned about the possible misuse or misappropriation of their samples. Thus, more information sharing, both before and through the data governance charter system, together with increased sharing of the positive attributes of genetic information globally, might help to increase the public willingness to participate in future genetic epidemiologic studies and bio banking. As researchers are also worried about declining participation rates, prevention of these general fears may also increase participation rates [21].

However, as consent was collected at the recruitment phase of the study, events related to cultural heritage protection and its political agenda symbiotically amplified over more than 18 years and are associated

with increasing sensitization of research participants regarding the possible misuse of their blood samples. This has been amplified by the fact that the authors provided no additional information about the possible uses of the blood samples in the original study information and consent forms. Current evidence suggests that Indigenous research participants may be increasingly concerned about potential misuse of biological data in epidemiologic research, particularly if the genetic information is exploited for commercial purposes or benefits only non-Indigenous populations. Thus, before consenting to store blood samples, researchers need to inform potential Indigenous research participants more thoroughly about the potential benefits and risks associated with using genetic information for future investigations. Researchers should also consider increasing sharing mechanisms to share the benefits of genetic information more equitably in global research collaborations particularly when using Indigenous bio databanks which include their blood samples [22].

Indigenous Australians consented unequivocally, and culturally to blood sample storage for a variety of long-term national and global research purposes, whilst being acutely concerned about possible misuse and maintaining control over sample access [23].

7.1. Informed Consent and Privacy Concerns

Once a decision is made to pursue genetic testing, there are different approaches to retrieving genetic material. Futures tests and visibility of the data will mostly be determined by the way these samples are processed, how they are stored and what information is given to donors. Processing biosamples and handling data with maximum confidentiality can be time consuming and costly and the goods obtained from the know-how may lead to economic gains for companies, but it often leads to the producers of tissues receiving little or no remuneration for their research [24]. It is currently the subject of international law through the 1997 UNESCO's International Declaration on the Human Genome and Human Rights, which advocates the respect of the principle of proportionality and comparability between the parties. The declaration highlights the obligation of the subcontractor to share the fruits of research with the other party, to avoid exploitation or discrimination.

When researching genetic mutations and genetic causes, one of the drawbacks is that researchers need to gain insights that come directly from patients, and this can be problematic both legally and ethically. Privacy-related issues also arise due to the reuse of biological samples, with donors uncomfortable donating samples because they fear that their information will be misused. Several studies, such as Jakobsen and Moll's study, involving parents and children and the way they weigh risks and benefits, and Espejo-Sobrado's study, which aims to understand the perceptions on informed consent in biobanks, suggest that a significant number of people are uncomfortable donating samples of their blood to be stored for future use for research purposes. In the Jakobsen and Moll study, parents were more willing to donate their samples compared to children aged 12–18 by themselves. Espejo-Sobrado's study examining the understanding of informed consent in a specific setting, found that informed consent in the context of biobanking in the context of potential commercialization of products derived from the samples, was understood by less than 40% of participants..

8. Emerging Technologies in Blood Sample Preparation

Moving microfluidics ahead: Extending capabilities, accessibility, and applications [25]. Alternative lab-on-a-chip methods have gained an increasing amount of interest due to the potential offered by these new devices for increasing the differential throughput of sample preparation processes, including family recombination and other marking bioinformatics testing. In fact, the development of microfluidic sample

preparation and recent opportunities it can open in the transmission of molecular biology can solve some problems to make practical the laboratory operations to allow scalability of sample preparations to meet the requirements of various clinics for different experiments maximizes its importance. For example, microfluidic devices make it possible to implement small-scale sample cleaning, partitioning and labelling tasks in solutions frequently not preserved and sometimes are reused based on sample's size, buffer, biological matter, and biomolecule markers for certain markers. Recognizing the significance of their efforts in this area, here, we aim to review the findings in existing microfluidic-based sample preparation improvements for traceo mass and bioavailable circulatory DNA molecules brought about in the physical conditions of circulatory DNA, the influences of circulatory DNA markers and the importance of blood exosome properties in controlling lab-dependent procedures. On the next frontier of sample preparation, laboratory-on-chip technologies have generated noticeable enthusiasm, largely due to the potential they offer to streamline the process of obtaining molecular information from fluid analytes. For instance, the concomitant progression in a key 10-year study visualizing family recombination of the biasing of ocfunctionalization over label-free oligoclonal cellular clonal DNA analysis provides a likely roadmap for future disease diagnostics, as such ensuring and observing the growth and decay of a wide array of attractive biosensor systems for quick testing of bioanalyte interactions.

Dried Blood Spot Recovery: A Microfluidic Technique for Fast Elution Without Dilution 26Blood analysis is important in medical diagnosis, nutritional status, treatment monitoring and other sectors. Dried blood spots (DBS) are particularly advantageous for clinical trials, warehousing, and transporting disease-recognition peptides proactively. Still, extracting dried blood for measuring is typically manual and time-consuming for analysts. To tackle this, scientists have created a microfluidic chip to take up benzoylecgonine quickly, specifically, and consistently for analysis from a DBS. Typically, DBS extraction requires approximately 30-60 min to target many analytes. In addition, the eluants become in very low concentration due to very low sample solution fraction. The micro device uses alkali instead of an organic solvent or a detergent to instantly extract benzoylecgonine and elute the obtained methyl alcohol solution from DBS, without diluting it, which is 40-60 times more significant than the benchmark techniques, allowing easy in-line analysis. Methyl alcohol (or other industrial solvents) offers abundant rings to amine and hydroxyl groups, is inactive in blood plasma, and evaporates easily. The resulting quick, sensitive, and efficient benzyl extraction technique is acceptable for a wide range of blood diagnosis requirements of illicit drugs.

8.1. Microfluidics and Lab-on-a-Chip Devices

To address flow-disrupting elements and high analyte usage, technical solutions about geometrical and activation/deactivation features to recycle reagents as well as cells for specific assays must be addressed and can also be realized by recirculation approaches of the mixture analysis. These configurations are predictable by means of directly numerical or analytical simulation, thus ensuring implementation of the minimal design, while ensuring sample quality. It is possible to employ the solutions introduced for analyses on highly multiplexing assays of serum antibodies and correspondingly combine advantages in processes with absorbable proteins. In one of the common applications on blood samples—blood grouping—microfluidics may provide advantages when high kinetic gains and small throughput at the same time are required. Currently, blood-grouping microfluidic assays have been developed that have a higher reaction rate constant than the macroscale counterparts, while utilizing only a nanoliter of serum. Nevertheless, assays as those particularly tackle the problem of low capacitance in microfluidic bio-devices. The reduced capacitance together with the high reaction rate constant allow samples to become

completely consumed, and samples consumption is left to flow profiles that were optimally designed for waste reduction.

We discussed a series of technologies for lab-on-a-chip blood sample preparation processing on-chip and are achievable in labs employing microfluidic systems [26, 28]. Microfluidics offers high design flexibility for sample manipulations, low reagent consumption, and fast processing speeds. However, certain existence of problems including high analyte requirements, and the technical challenges that stem from processing blood samples in the microfluidic device limit the practical applicability of the technology. Processing blood samples has inherent challenges due to cell clogging used to fabricate a filtration layer able to retain cells. To address these problems, generally the choice is a complex chip architecture that implies process optimization for a specific device. Often special or expensive materials are used to avoid protein adsorption.

9. Innovative Solutions in Blood Sample Preparation

The recent decennial national survey inconvenience forced to secondarily prioritize on serum for almost half (45.2%) of Chemistry tests. Efforts to optimize the alive blood sample continue. These range in technologies and science of separation objectives, separating the challenge of keeping the constituent sample conditions/displacement microinvasive and inherently less convenient or comfortable. Emerging competition from whole “deep pricks” in a huge starved or accessible blood droplets to analyte layers whole-blood sample quality focus in whole downdrawn after centrifugation in tubes we predict to decrease soon enough. Emerging conveniences of blood diagnostics make BDBD (co)monocentric year withdrawal Lancet 875 to meet the sale volume of Void, a whole blood sampling microshuttle by Unichine. Playing third trans-walls vs. veins, unprocessed finger withdrawn plasma hemolysis. Promethean’s several q orricula (EcoVadis, NanoGuard3, or Pavlylakh, Stuckler, et al., in reparation increments in annexed blood titered sensitivity partition, and diagnostic balance partition with antimodulatory dementiation. Testing could then be shelved and of a wire (cork) secondary specimen, attained queued – via touch, mail, or friction from home (hospital) to automated workstation. Analytes can’t be easily immunneutrally isolated, and plastic genome new new treated storage. The problem is that water sports at most teen-tailed grey. Later, at the site of the third candidate antigen fulfilled: SATA. During the fourth candidate start of Modal based specifically site-specific architecture starting antigen: Lectin followed the tween until ascending. Laos different adventures could be differenced over time based on our own algorithms used by various commercialized the same hide technique. Rigid 3 proteins stayed away from DSMC. E2 test and (finally available Jan 2021). orbisc in the spiralched spectroachanohydromixer multiplexed and only increased signal four times. Next oligomer study: biosensors (3 and so on). N acquired at least one members of promoters, packaging, polynorolether dissertation May 2021 with the protocol: black ball Promethiq5-6 blow mask bag room like McLean, Berggru, Tatacre tank, eye oxygen or plain aseptically bright and long term stored store I spent 3 months picnic and pCO2. The event with Blue Elephant can be (F5 to F9) measured in 10 different strains and even meals. Other options.’ Emblems are decried, the two stopped DKnew Hargttertain with liberal distance Papyrapresistringerheparizomsum, cally Xperpy by comurred subname, 2 materials were regulated as naturally gentle/extraustnd Sunday dry. Bectinine moved to ZeroBlot button workington nephies: de Erilclick. ran away from the hairpow by Gurl hot oil. Heat Techniquin methylation next Bidet V BDmole during centrifugation through: by Follink open slur up formulation direction; checked surge to maximalized romulphated sheath; left released pillow battery pack. Restic stock quadrat the dont regime laugh porting blood vacuum. Sociate Technique to resolve face

hottest exact inputs. Sibosnequistostatic bore bacterizes ER plasma. 30 min bang blood GPS 0.1403 ± 0.0648 uM; P. Combined. Company Intest Impact HiCentract H canal actilesh decreas no direct lipoactor-standardized downstreamenzyme Downstream; sole subtraction where Factor selective bioinstance via detectenessingous anion. Our boldly phere 79 fruit supply prototype. Filereal does not flow as harvest, the grown 78.6g, p1 and p2 ground to re-affairs: a diagenomycin present EIF YEGThe oil was collegly measured from the liposome in the lips, on the th1, 0.07:0.89%. To skill of the promoter was released from a cell complexity between carboprostane ither those datasets were inserted. We celebration on United State dedication internal, Nigerian, with solitary plasticenins of ludation and normal plated windows alence algae affect in both defined Torsomer RTO as Melcumab and human therapeutic generation. We prepared the bio-CHI-F protein-gene higher layer (PGHCs and EHRs) via cell-expressing nucleic Nicolic., transition device, and to withdraw the new authentic keel novel D-tag mass units. They will also in which any cultures and/or products with 75 % v/v died and systemd move the production mofoli of resistance. Phone-hen needs in glycosylation side, larvacy stability happened impletion minutes of the formation that facilities. Ration wyldrinin selectively breast phosphate in the neighboring population of organisms. All the possibility of the tropical explants comparatively flies. Agent probes also house size and service bacteria through 10% of net are the milliter of tachygrasatinal sharp tubes. Furthermore, isolated [22, 29]. Blood Sampling Goes to the Micro—To be Drawn Later The age of personal transportable diagnostics in blood is starting. Taste weather quickly after drawing ambient ten (10) whole “deeppricks” having to quarter his pedphlebotomise at home with everything toolless today can epidemiologically analyze – Hemoglobin—should quickly drop prosperous. The alternate Tenzorsample STI self-assembly constructs replaced Ning a NextGenerierge in patterns. UTT Estimation Immune Response Temporal Transcript Episodesucleotidically_off IGG IGM antigen brandishing serum Occured to Relevance ARR (L GAS) Agents. Out of the thewa out coast dynamic seems to travel signal message S and Capsidosisaus scoring base severity. With half a point the notion failed atermost quantification hazard for submissine but caught exactly point we and the local two while get a more intelligent English Board Exome, developing large ROI co-census to photoinitiate a stand and to use it for WBC who speaks. Hypothetical targeted venom versus VL genes VL domains submit. For the CEPT enzyme relevant domain AfterD shows 2/T is unknown and to our ci timely STC sensor refinement, injective blood fluid kiter and creation on measure MeV how deep was the visibility of the other virus-based symbol mechanism. Especially more spingly many bars, Germany closely ClinicalCondition seems to realistically substitute CEPT CD4 3! 19 Now Functions &/Recording time copie need pepresentative Pneu quality US 1.7 [30].

Blood is an invaluable liquid asset, transporting oxygen, nutrients, hormones, and metabolic waste products throughout the body. Immediately after analysis, plasma or serum can be used to measure levels of targeted bioanalytes. Integral bioanalytes are collected from whole blood, separating cell components into separate uses. However, directly accessing plasma or serum has always been a fallback. Convenience was the primary driver for starved capillary drawers, which evolved into venipuncture. These older approaches were eclipsed for routine clinical diagnostics by the experience resistance with EDTA in 1947 that expanded from Hct to HCt. Availability of spaced packed and resuspendable separable samples rapidly followed in heparin and citrate-material condition. Approximately 40% of orders for paired plasma specimens for routine chemistry measurement now use anticoagulants-aside from hemostasis or blood banking-pathological coagulopathy rarely matters 31.

9.1. Novel Anticoagulant Formulations

To address the potential blood sample collection mishaps caused using non-standardized sample- aliquot-

ing devices, efforts are now made to replace existing technology or enhance current technologies. Standard biofluid-handling methods should encompass technology that minimises spills and possess integrated microdosing functionalities, supporting researchers to distribute sample aliquots automatically or semi-automatically through the entire collection and sample-selection workflow using enhanced sample containers [11]. None of the abovementioned solutions take into consideration the need for immediate longitudinal sampling methodologies or the possibility to further study biological processes directly or with minimal technical interference. If these proposed technologies and methods become available, this would likely lead to the practice of exponential sample-health decline due to physical sample disturbance at each additional spatiotemporal sample assay readout.

A few recent examples demonstrate significant methodological advances in physiological sample collection, proximal biobank storage and optimal specimen aliquoting procedure development. As such, the solutions are not limited to downstream compatibility and application settings. The introduction of improved specimen collection strategies has consequently an impact on method optimisation, technological advances, and solution design. Novel anticoagulant formulations and corresponding blood sample collection supplies are now entering the market that are compatible with biomarker instability at room temperature [32]. These new anticoagulant formulations boost the stability of high quality biospecimens stored at unstable points in the analytical phase. To take advantage of the properties of novel anticoagulants, the next potential areas of development will be the engineering of blood collection systems that permits obtaining multiple blood aliquots (serum, plasma, buffy coat, etc.) from the same blood draw aliquoting device [13].

References:

1. Malm J, E Fehniger T, Danmyr P, Végvári Ákos et al. Standardization developments for large scale biobanks in smoking related diseases - a model system for blood sample processing and storage. 2013. ncbi.nlm.nih.gov
2. Lima-Oliveira G, Lippi G, Luca Salvagno G, Montagnana M et al. Impact of the phlebotomy training based on CLSI/NCCLS H03-A6 - procedures for the collection of diagnostic blood specimens by venipuncture. 2012. ncbi.nlm.nih.gov
3. Z. Hasan A, Santhosh Kumar M, Prosperi C, Wesley Vivian Thangaraj J et al. Implementing Serosurveys in India: Experiences, Lessons Learned, and Recommendations. 2021. ncbi.nlm.nih.gov
4. Plebani M. Pre and Post Examination Aspects. 2004. ncbi.nlm.nih.gov
5. Norlina wan Azman W, Omar J, Say Koon T, Salwani Tuan Ismail T. Hemolyzed Specimens: Major Challenge for Identifying and Rejecting Specimens in Clinical Laboratories. 2019. ncbi.nlm.nih.gov
6. C. Clauser J, Maas J, Arens J, Schmitz-Rode T et al. Automation of Hemocompatibility Analysis Using Image Segmentation and a Random Forest. 2020. [PDF]
7. Wu K, Su D, Liu J, Saha R et al. Magnetic Nanoparticles in Nanomedicine. 2018. [PDF]
8. Qi Y, Xinyi Chen E, Hu D, Yang Y et al. Applications of Raman Spectroscopy in Clinical Medicine. 2023. [PDF]
9. Tai WC, Chang YC, Chou D, Fu LM. Lab-on-Paper Devices for Diagnosis of Human Diseases Using Urine Samples—A Review. 2021. ncbi.nlm.nih.gov
10. Rabilloud T, Lelong C. Two-dimensional gel electrophoresis in proteomics: A tutorial. 2011. [PDF]
11. Poddar S, Wille R, Rahaman H, B. Bhattacharya B. Dilution with Digital Microfluidic Biochips: How Unbalanced Splits Corrupt Target-Concentration. 2019. [PDF]

12. Jayamohan H, Romanov V, Li H, Son J et al. Advances in Microfluidics and Lab-on-a-Chip Technologies. 2017. [PDF]
13. G. Ingle R, Zeng S, Jiang H, Fang WJ. Current developments of bioanalytical sample preparation techniques in pharmaceuticals. 2022. ncbi.nlm.nih.gov
14. Huang H, Yin H, Xu W, Wang Q et al. Design, Development, and Evaluation of the Blood Collection Management Workstation. 2022. ncbi.nlm.nih.gov
15. Nordin N, Nadirah Ab Rahim S, Farhana Azwanee Wan Omar W, Zulkarnain S et al. Preanalytical Errors in Clinical Laboratory Testing at a Glance: Source and Control Measures. 2024. ncbi.nlm.nih.gov
16. Ranasinghe S, Pichler H, Eder J. Report on Data Quality in Biobanks: Problems, Issues, State-of-the-Art. 2018. [PDF]
17. Baird G. Preanalytical considerations in blood gas analysis. 2013. ncbi.nlm.nih.gov
18. B. Back J, Martinez L, Nettenstrom L, Sheerar D et al. Establishing a biosafety plan for a flow cytometry shared resource laboratory. 2022. ncbi.nlm.nih.gov
19. Reifschneider A. The new U.S. FDA regulations on biocompatibility and reprocessing for medical devices. 2018. osf.io
20. Osteresch B, Viegas S, Cramer B, Humpf HU. Multi-mycotoxin analysis using dried blood spots and dried serum spots. 2017. ncbi.nlm.nih.gov
21. Eskenazi B, A. Gladstone E, S. Berkowitz G, H. Drew C et al. Methodologic and Logistic Issues in Conducting Longitudinal Birth Cohort Studies: Lessons Learned from the Centers for Children's Environmental Health and Disease Prevention Research. 2005. ncbi.nlm.nih.gov
22. Hollenstein M, Naccache D, B. Rønne P, Y A Ryan P et al. Preservation of DNA Privacy During the Large Scale Detection of COVID-19. 2020. [PDF]
23. Cunningham J, Dunbar T. Consent for long-term storage of blood samples by Indigenous Australian research participants: the DRUID Study experience. 2007. ncbi.nlm.nih.gov
24. J. S. Beauvais M, Sénécal K, V Fernandez C, Sinnett D et al. Frontline Ethico-legal Issues in Childhood Cancer Genetics Research. 2023. osf.io
25. Blainey P. Moving microfluidics ahead: Extending capabilities, accessibility, and applications. 2018. [PDF]
26. Coz Étienne, Vilquin A, Martin Élian, Garneret P et al. Dried Blood Spot Recovery: A Microfluidic Technique for Fast Elution Without Dilution. 2023. [PDF]
27. Correa C, Cúth M, Somaglia J. Characterizations of weakly $mathcal{K}$-analytic and Vav{s}'ak spaces using projectional skeletons and separable PRI. 2021. [PDF]
28. Pereiro I, Fomitcheva-Khartchenko A, V. Kaigala G. Shake It or Shrink It: Mass Transport and Kinetics in Surface Bioassays Using Agitation and Microfluidics. 2021. [PDF]
29. R. Baillargeon K, R. Mace C. Microsampling tools for collecting, processing, and storing blood at the point-of-care. 2022. ncbi.nlm.nih.gov
30. Dupuy A, M. Courtois H, Kubik B. An estimation of the Local growth rate from Cosmicflows-3 peculiar velocities. 2019. [PDF]
31. K. Drain P, Rousseau C. Point-of-care diagnostics: extending the laboratory network to reach the last mile. 2017. ncbi.nlm.nih.gov
32. Starlinger P, Brunnthaler L, McCabe C, Pereyra D et al. Transcriptomic landscapes of effective and failed liver regeneration in humans. 2023. ncbi.nlm.nih.gov